Global Hemorrhagic Shock Treatment Market, By Drug Type ( NVX-408, YW-356, LB-1148, Neutrolide, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Channels ) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 206.3 Million in 2023 and is expected to exhibit a CAGR of 4.4 % during the forecast period (2023-2030), as highlighted in a new report published by Coherent Market Insights.
The strategies by key market players like research and development is expected to drive the global hemorrhagic shock treatment market growth over the forecast period. For instance, on April 9, 2020, Pharmazz, Inc., a biopharmaceutical company announced that centhaquine, a drug in the final stage of development, can provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome (ARDS), reduce multiple organ dysfunction scores (MODS) and decrease mortality in patients with coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
Global Hemorrhagic Shock Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries, such as India, China, Brazil, and others faced problems regarding the transportation of drugs from one place to another.
COVID-19 had a negative impact on the global hemorrhagic shock treatment market. For instance, on July 10, 2020, according to an article published by The Cleveland Clinic Journal of Medicine, septic shock appears to be the predominant cause of distributive shock in patients with COVID-19, secondary to the virus itself or bacterial co-infections. COVID-19 has also been associated with a hyper-inflammatory immune response with elevated cytokine levels termed cytokine storm or cytokine release syndrome. This syndrome leads to loss of vasomotor tone and higher rates of mortality. The occasional greater need for sedation in severe cases of COVID-19–associated pneumonia may cause hypotension from direct medication effect or blunted sympathetic drive.
Global Hemorrhagic Shock Treatment Market: Key Developments
For instance, on September 29, 2021, Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced that its Phase III clinical study of the drug candidate, centhaquine, has been approved by the U.S. FDA for the treatment of hypovolemic shock. Centhaquine converts venous unstretched blood volume to strained blood volume and improves cardiac output and blood flow, making it an ideal candidate for the resuscitation of patients. Centhaquine increased cardiac preload and decreased cardiac afterload to increase cardiac output during resuscitation. In patients with uncontrolled bleeding, damage control resuscitation is performed to stop blood loss and initiate resuscitation, with permissive hypotension in mind with a mean arterial pressure of 65 mmHg. Resuscitation with sentachin limits the use of blood, blood products, and vasopressors and helps achieve resuscitation without artery constriction.
Browse 47 Market Data Tables and 43 Figures spread through 280 Pages and in-depth TOC on Global Hemorrhagic Shock Treatment Market, By Drug Type ( NVX-408, YW-356, LB-1148, Neutrolide, Others), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Channels ) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in this market, click the link below:
https://www.coherentmarketinsights.com/market-insight/hemorrhagic-shock-treatment-market-4097
Key Takeaways of the Global Hemorrhagic Shock Treatment Market:
- Global hemorrhagic shock treatment market is expected to exhibit a CAGR of 4.4 % during the forecast period. For the treatment of hemorrhagic shock for instance, on September 26, 2022, an article published by National Center for Biotechnology Information explained hypotensive resuscitation has been used for the hemorrhagic shock patient without head trauma. The aim is to achieve a systolic blood pressure of 90 mmHg in order to maintain tissue perfusion without inducing re-bleeding from recently clotted vessels. Permissive hypotension is a means of restricting fluid administration until hemorrhage is controlled while accepting a short period of suboptimal end-organ perfusion.
- Among region, North America is expected to be the dominant region in the global hemorrhagic shock treatment market, owing to the increasing treatment for patients with hemorrhagic shock in the region. For instance, an article published by National Center for Biotechnology Information on September 26, 2022, explained recent trends in damage control resuscitation focus on “hemostatic resuscitation,” which pushes for the early use of blood products rather than an abundance of crystalloids in order to minimalize the metabolic derangement, resuscitation-induced coagulopathy, and the hemodilution that occurs with crystalloid resuscitation. The end goal of resuscitation and the ratios of blood products remain at the center
- Major players operating in the global hemorrhagic shock treatment market include Biomedica Management Corporation, NuvOxPharma LLC, Leading BioSciences, Inc, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Johnson & Johnson Services Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Teva Pharmaceutical Industries Ltd., Novartis AG, ZydusCadila, Amneal Pharmaceuticals LLC.
